title: Evidence for treatment strategies in sinonasal adenocarcinoma.
abstract: Adenocarcinomas of various types account for 10% to 20% of all primary malignant neoplasms of the nasal cavity and paranasal sinuses. There is a general consensus that the optimal treatment of adenocarcinoma is surgery and postoperative radiotherapy. The purpose of this report was to review the results of this combined treatment as well as other treatment strategies and their outcome. Most series present outcome data from a heterogeneous group of patients, with a wide variety of tumor subtypes presenting at differing stages, who received a variety of treatment strategies. Surgical excision remains the treatment of choice. The choice of approach is determined by what will best allow complete excision of the disease. Endoscopic techniques, if feasible for complete removal of the tumor, offer results comparable to those of external approaches with lower morbidity. Although clear evidence to support the use of radiotherapy in sinonasal adenocarcinoma is difficult to obtain, local control rates of combined treatment strategies for advanced cases are comparable to less advanced cases with surgery alone, suggesting a positive role for postoperative radiotherapy. However, the importance of thorough surgical resection should be stressed.
authors.affiliation: Ear Institute, University College London, London, United Kingdom.
authors.forename: Valerie J
authors.initials: VJ
authors.lastname: Lund
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Chisholm
authors.forename: Robert P
authors.initials: RP
authors.lastname: Takes
authors.forename: Carlos
authors.initials: C
authors.lastname: Suárez
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: Alessandra
authors.initials: A
authors.lastname: Rinaldo
authors.forename: José L
authors.initials: JL
authors.lastname: Llorente
authors.forename: Chris H J
authors.initials: CH
authors.lastname: Terhaard
authors.forename: Juan P
authors.initials: JP
authors.lastname: Rodrigo
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Maughan
authors.forename: Alfio
authors.initials: A
authors.lastname: Ferlito
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009296:Nasal Cavity / Q000473:pathology* / Q000601:surgery; D020360:Neoadjuvant Therapy; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013517:Otorhinolaryngologic Surgical Procedures; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011878:Radiotherapy; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents